Browsing: Semaglutide

The cosmetic consequences of using the diabetes medication Ozempic for off-label weight loss are becoming increasingly visible. Dubbed “Ozempic face,” this phenomenon describes the rapid ageing and sagging of facial skin seen in some users.

As the world shifts its focus from the immediate threat of the COVID-19 pandemic, another health concern, often silent but equally impactful, is gaining prominence. Non-alcoholic Fatty Liver Disease (NAFLD), recognised as the “silent epidemic,” has emerged as a significant global health issue, affecting an estimated 38% of the world’s population.

With the emergence and increasing popularity of glucagon-like peptide 1 (GLP-1) agonists for the treatment of obesity in recent years, it might be worth investigating if these agents are able to reduce the cardiovascular risks associated with overweight and obesity, especially since they have been shown to reduce risk of major adverse cardiovascular events in patients with type 2 diabetes who are at high cardiovascular risk.

Log In or Register as a healthcare professional to read the full article.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) have increased significantly in recent years due to its marked efficacy in body weight reduction in clinical trials and most recently, due to claims by celebrities and social media personalities that they have lost weight after using Ozempic (Semaglutide). While there were earlier concerns on supply shortage due to high demand of on-label and off-label use, there has been reports of a new adverse event signal that has drawn scrutiny from health authorities in the United States (US), European union (EU) and in Asia about its possible link to suicidal episodes. 

Log In or Register as a healthcare professional to read the full article.